Description: Lipidor AB (publ), a pharmaceutical development company, engages in the development of drugs for the treatment of psoriasis, bacterial skin infections, and atopic dermatitis. The company develops AKP-01, which is in Phase III for the treatment of psoriasis; and preclinical stage products, such as AKP-02 for psoriasis, and AKP-03 AKP-07 for eczema. It offers active pharmaceutical ingredients used in products for various therapeutic applications, such as anti-psoriasic, antimicrobial, anti-inflammatory, antifungal, local anesthetics, non-steroidal anti-inflammatory, anti-acne, wound healing, anti-eczema, and anti-migraine. The company also develops a range of spray products for animal skin care in dogs, cats, and horses; and consumer health care products for applications, including antibacterial, antiseptic, moisturizing emollient, disinfectant, and acne and wart treatment. It has a collaboration agreement with Cannassure Therapeutics Ltd. for the development of topical medicinal cannabis products for the treatment of skin inflammations and psoriatic lesions. The company was incorporated in 2009 and is based in Danderyd, Sweden.
Home Page: lipidor.se
Svärdvägen 13
Danderyd,
182 33
Sweden
Phone:
46 7 25 07 03 69
Officers
| Name | Title |
|---|---|
| Mr. Ola Holmlund | Chief Exec. Officer |
| Mr. Olle Holmertz | Founder & Bus. Controller |
| Mr. Anders Carlsson Ph.D. | Co-Founder, Sr. Advisor & Chief Devel. Officer |
| Dr. Bengt Herslöf | Co-founder & Sr. Scientific Advisor |
| Dr. Jan Holmbäck Ph.D. | Co-Founder & Chief Scientific Officer |
| Dr. Gerhard Miksche | Co-Founder |
| Ms. Charlotta Ekman | Chief Financial Officer |
| Mr. Anders Hagman | Chief Devel. Officer |
Exchange: ST
Country: SE
Currency: Swedish krone (kr)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 10.5934 |
| Price-to-Sales TTM: | 67.346 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 6 |